Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Effect of host and viral factors on hepatitis B e antigen-positive chronic hepatitis B patients receiving pegylated interferon-α-2a therapy.

Antiviral therapy - 1 Jan 2011

Tseng Tai-Chung, Yu Ming-Lung, Liu Chun-Jen, Lin Chih-Lin, Huang Yi-Wen, Hsu Ching-Sheng, Liu Chen-Hua, Kuo Stephanie Fang-Tzu, Pan Corinna Jen-Hui, Yang Sheng-Shun, Su Chien-Wei, Chen Pei-Jer, Chen Ding-Shinn, Kao Jia-Horng

Abstract excerpt

BACKGROUND: Pegylated interferon (PEG-IFN)-α-2a improves the hepatitis B e antigen (HBeAg) seroconversion rate in HBeAg-positive chronic hepatitis B patients. However, baseline factors predicting favourable responses to PEG-IFN-α-2a remain largely unknown. METHODS: A total of 115 HBeAg-positive chronic hepatitis B patients who had a pre-therapy serum alanine aminotransferase (ALT) level over two times the upper...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Hepatitis B, Chronic
Share to Hepatitis B e Antigens

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to HLA-DP alpha-Chains

Share to HLA-DP beta-Chains

Share to Hospitals, University

Share to Interferon-alpha

Share to Polyethylene Glycols

Share to Viral Load

Source

Identifiers

PMID: 21817184
DOI: 10.3851/IMP1841

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Effect of host and viral factors on hepatitis B e antigen-positive chronic hepatitis B patients receiving pegylated interferon-α-2a therapy.PMID 21817184Read ↗

Peginterferon α in the treatment of chronic hepatitis B.Semantic proximity Read ↗

Importance of host genetic factors HLA and IL28B as predictors of response to pegylated interferon and ribavirin.Semantic proximity Read ↗

Hepatitis B virus genotype B results in better immediate, late and sustained responses to peginterferon-alfa in hepatitis-B-e-antigen-positive patients.Semantic proximity Read ↗

Genetic polymorphisms in interferon pathway and response to interferon treatment in hepatitis B patients: A pilot studySemantic proximity Read ↗

Polymorphisms of HLA-DP are associated with response to peginterferon in Caucasian patients with chronic hepatitis B.Semantic proximity Read ↗

Hepatitis b infection: progress in identifying patients most likely to respond to peginterferon alfa.Semantic proximity Read ↗

Association of vitamin-D-related genetic variations and treatment response to pegylated interferon in patients with chronic hepatitis B.Semantic proximity Read ↗

Polymorphisms of CYP27B1 are associated with IFN efficacy in HBeAg-positive patients.Semantic proximity Read ↗

Genetic polymorphisms in interferon pathway and response to interferon treatment in hepatitis B patients: A pilot studySemantic proximity Read ↗

Role of CYP27B1+2838 promoter polymorphism in the treatment of chronic hepatitis B HBeAg negative with PEG-interferon.Semantic proximity Read ↗

Relevance of baseline viral genetic heterogeneity and host factors for treatment outcome prediction in hepatitis C virus 1b-infected patients.Semantic proximity Read ↗

Distinct evolution and predictive value of hepatitis B virus precore and basal core promoter mutations in interferon-induced hepatitis B e antigen seroconversionSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.